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Abstract
Over two decades of MDM2 research has resulted in the accumulation of a wealth of knowledge 
of many aspects of MDM2 regulation and function, particularly with respect to its most prominent 
target, p53. For example, recent knock-in mouse studies have shown that MDM2 heterooligomer 
formation with its homolog, MDMX, is necessary and sufficient in utero to suppress p53 but is 
dispensable during adulthood. However, despite crucial advances such as these, several aspects 
regarding basic in vivo functions of MDM2 remain unknown. In one such example, although 
abundant evidence suggests that MDM2 forms homooligomers and heterooligomers with MDMX, 
the function and regulation of these homo- and heterooligomers in vivo remain incompletely 
understood. In this review, we discuss the current state of our knowledge of MDM2 
oligomerization as well as current efforts to target the MDM2 oligomer as a broad therapeutic 
option for cancer treatment.
INTRODUCTION
The most commonly mutated gene in cancer is TP53,1,2 which encodes the transcription 
factor p53. Involved in a multitude of stress responses, p53 upregulates the transcription of 
genes involved in cell cycle arrest, apoptosis, metabolism and DNA repair.3-7 In almost all 
cancers, p53 signaling is disrupted, either directly through mutations that impair p53-
directed transcription or indirectly through the mutation of genes involved in p53 regulation. 
Interestingly, many tumor-associated point mutations in p53 result in gain-of-function 
effects that result in worse patient outcomes.8,9 The frequency of p53 signaling disruption in 
cancer illustrates the importance of normal p53 function for tumor suppression. Indeed, 
when considered in the context of numerous p53 mutant mouse models and the biology of 
human tumorigenesis, one can easily grasp why p53 has long been dubbed the ‘guardian of 
the genome’.10
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One of the best known regulators of p53 is MDM2, which is an E3 ubiquitin ligase capable 
of ubiquitinating p53, thereby marking p53 for proteasomal degradation.11-13 MDM2 has 
also been shown to inhibit p53 transcriptional activity directly through binding to the 
transactivation domain of p53.14,15 MDM2 remains the most experimentally consistent 
ubiquitously expressed ubiquitin ligase that can effect the degradation of p53 in vitro and in 
vivo. Therefore, although p53 has been referred to as the ‘guardian of the genome’, MDM2 
can be thought of as the guardian of the ‘guardian of the genome’. MDM2 is frequently 
overexpressed in several types of tumors (many of which harbor wild-type (WT) p53),16-20 
which has led to increased interest in developing drugs that inhibit MDM2 activity to 
stabilize and activate p53.21 However, many drugs that have shown promise in preclinical 
models have failed to translate into therapeutically effective drugs. One factor that could 
contribute to the eventual success of p53-activating drugs is a more comprehensive 
understanding of MDM2 function. For example, although we know that MDM2 requires the 
ability to oligomerize to efficiently ubiquitinate p53,22-24 understanding the mechanics, 
function and regulation of MDM2 oligomerization could be useful to optimize the potency, 
specificity and synergy of p53-activating drugs. In this review, we discuss our current 
understanding of MDM2 function with an emphasis on evidence of MDM2 oligomerization 
and function in p53 regulation. We discuss the importance of the MDM2–MDMX (also 
known as MDM4) heterooligomers and the evidence of MDM2 homooligomer function. 
Although MDMX shares many structural features with MDM2, it is less understood and less 
studied than MDM2 (12-fold more MDM2 publications than MDMX accessible on 
PubMed). We further speculate on potential models that could help explain in vivo MDM2 
behavior. Finally, we end with a discussion of efforts to target MDM2 oligomers to restore 
p53 activity in tumors.
BACKGROUND
MDM2 is a member of the RING (Really Interesting New Gene) domain-containing E3 
ligase family and contains at least three distinct regions that are highly conserved and critical 
to its function as an E3 ligase for p53. These three domains include an N-terminal p53-
binding domain, a central acidic/zinc finger domain, and a C-terminal RING domain (Figure 
1). The p53-binding domain, which resides within the first ~ 100 amino acids, is necessary 
for substrate recognition and transcriptional inactivation of p53.14,25,26 The isolated MDM2 
p53 binding pocket, which minimally involves amino acids 25–108,27 appears to be 
sufficient to bind p53, at least in vitro.26 The central acidic domain (AD), which can be 
considered to include the central zinc finger domain (residues 300–326), has been largely 
characterized as a regulatory domain; the AD binds to several small proteins that can inhibit 
MDM2 and stabilize p53. The AD and adjacent intervening sequence can also be post-
translationally modified by various kinases, including ATM (ataxia telangiectasia 
mutated),28 ATR (ATM-related),29 c-Abl,30 Akt,31 casein kinase 1δ32 and casein kinase 2,33 
which serves as another way (or a prerequisite) to achieve MDM2 enzymatic regulation 
(Figure 1). Although less well studied, some of these kinases also modify residues on the 
MDM2 homolog MDMX, which could contribute to the regulation of MDM2 function and 
p53 stability.34-36 A summary of the basic ways in which MDM2 can be inhibited through 
the AD is shown in Figures 1 and 2. Finally, the RING domain is responsible for the 
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heterooligomerization of MDM2 with its homologous partner MDMX as well as for 
homooligomerization with other MDM2 molecules. The RING domain also contains the 
enzymatic activity of MDM2 and catalyzes the transfer of ubiquitin from the E2 to p53. The 
deletion of any of these three domains inhibits MDM2 function and stabilizes p53, 
suggesting that all three are required for MDM2-mediated p53 degradation.37-40 Other 
aspects of MDM2 worth noting include a nuclear localization sequence (residues 181–185) 
and a nuclear export sequence (residues 190–200), which are responsible for shuttling 
MDM2 into and out of the nucleus. Moreover, a cryptic nucleolar localization sequence has 
been identified near the C terminus of MDM2.41
In its functional configuration as an E3 ligase, MDM2 forms homooligomers and 
heterooligomers with MDMX.22,42 MDMX is structurally similar to MDM2 (Figure 1), 
which reflects its evolution through a gene duplication event from MDM2 ~ 440 million 
years ago.43 Despite extensive homology between these two genes (especially in the RING- 
and p53-binding domains), MDMX itself does not possess appreciable intrinsic E3 ligase 
activity toward p53.44,45 Recent mutational analyses offered insight into the basis for this 
difference in catalytic proficiency. Interestingly, only two point mutations (N448C and 
K478R) are sufficient to restore E3 ligase activity to the MDMX RING domain in vitro.46 
However, it appears as though additional regions of MDMX that deviate from MDM2, 
including the AD and the analogous nucleolar localization sequence region of MDMX, may 
be equally necessary to convert MDMX into a functional p53 E3 ligase in cells.47 MDMX 
also does not contain a nuclear localization sequence, which accounts for its predominantly 
cytoplasmic localization. Despite not possessing a nuclear localization sequence, MDMX 
can be transported to the nucleus by piggybacking onto MDM2 in a RING domain-
dependent manner.48 Purified MDMX RING domains have recently been shown to form 
oligomers suggesting that MDMX may also form homooligomers in cells.49 Interestingly, 
MDM2 transcription is upregulated by p53, forming an autoregulatory inhibitory feedback 
loop.50,51 For many years following its discovery, MDMX expression was thought to occur 
independently of p53 control;44,52 however, recent reports have identified a functionally 
active p53 response element within intron 1 of the MDMX locus.53,54 This response element 
can be induced in a p53-dependent manner in response to at least some stresses. Thus, 
MDM2 and MDMX appear to participate in negative feedback loops to control the p53 
response, which could have a role in the rapid attenuation of the p53 response when an 
apoptotic outcome is not warranted. MDM2 and MDMX also share the ability to inhibit p53 
transcriptional activity through direct binding and masking of the p53 transactivation 
domain.15,16 Another common thread between MDM2 and MDMX is their ability to be 
ubiquitinated by MDM2. At least under overexpressed conditions, MDM2 can auto-
ubiquitinate itself, and MDM2 can ubiquitinate MDMX in trans resulting in their respective 
degradation. Although MDM2 may be subject to degradation through other E3 ligases under 
physiological conditions,24 the ubiquitination of MDM2/MDMX by MDM2 offers an 
autoregulatory mechanism through which MDM2 can reduce its own activity. One of the 
major questions that remains to be determined is how MDM2 directs its ligase activity 
toward p53, MDMX or itself, such as in the context of the MDM2–MDMX–p53 ternary 
complex.55-57 Recent studies have suggested that binding of small proteins such as p14 
alternative reading frame (ARF) to the MDM2 AD could direct the substrate specificity of 
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MDM2 toward MDMX.58,59 Under non-stressed conditions, MDMX is thought to stabilize 
MDM2, which could contribute to the increased potency of MDM2–MDMX 
heterooligomers for p53 ubiquitination relative to MDM2 homooligomers.60-63 On the other 
hand, the absence of MDMX effectively stabilizes p53, as the deletion of the MdmX gene in 
mice (like the deletion of the Mdm2 gene in mice) results in an embryonic lethal phenotype 
that can be rescued by the concomitant deletion of p53.64 Nonetheless, several studies have 
shown that MDM2 alone is capable of ubiquitinating and degrading p53.22 Moreover, 
MDM2 may be sufficient for p53 degradation, as the conditional deletion of MdmX in adult 
tissue does not cause extensive p53 stabilization and apoptosis when compared with Mdm2 
deletion.65
Genetic mouse models have shown that the reactivation of p53 signaling is sufficient for the 
ablation of tumors.66-68 Moreover, the activation of p53 signaling appears to be specifically 
damaging enough to cancer cells to spare normal tissue from severe side effects from 
therapeutics that stabilize or restore the activity of p53. To fully capitalize on the potential of 
drugs that activate p53, such as MDM2 inhibitors, understanding how p53 is controlled by 
MDM2 oligomers is important. Moreover, to understand how to manipulate MDM2 
oligomers to stabilize p53, we must understand MDM2 oligomers in detail. In the following 
few sections, we discuss our current knowledge on MDM2 oligomer formation.
MDM2 OLIGOMERIZATION IN VITRO STUDIES
The initial pieces of evidence for MDM2–MDMX synergy have come from in vitro studies. 
In 1999, Tanimura et al.,22 and subsequently Sharp et al.,42 revealed that MDM2 binds to 
MDMX through their respective RING domains. By 2003, Linares et al.60 showed that 
MDMX enhances MDM2 E3 ligase activity. Subsequent studies revealed additional 
mechanistic details regarding the method of binding between MDM2 and MDMX. For 
example, although binding between the RING domains of MDM2 and MDMX was known, 
multiple studies showed that the extreme C-terminal tails (479–491 and 478–490 in human 
MDM2 and MDMX, respectively) of both proteins must be present for MDM2 
oligomerization and E3 ubiquitin ligase activity.69,70 Uldrijan et al.70 also showed that point 
mutations within the MDM2 extreme C terminus can be introduced that do not disrupt 
MDM2 oligomerization but inhibit p53 ubiquitination, suggesting that the extreme C 
terminus may participate directly in the ubiquitin transfer reaction. Moreover, the lengths of 
the extreme C-terminal tails of MDM2 and MDMX are highly conserved, and the addition 
of residues that extend the length of either C-terminal tail inhibits MDM2 E3 function but 
not homo- or heterooligomerization.71
Another milestone in understanding MDM2–MDMX heterooligomerization is the 
publication of an x-ray crystal structure of a heterooligomer between the MDM2 and 
MDMX RING domains.72 This structure was preceded by the nuclear magnetic resonance-
based resolution of the MDM2 RING domain homooligomer and the MDM2–MDMX 
RING domain heterooligomer in solution.73 These studies were largely consistent in 
describing the structure of the MDM2–MDMX RING heterooligomer; however, due to 
unstructured regions in MDM2, we lack full-length MDM2 protein oligomer structures. 
Without a full-length crystal structure of MDM2, determining whether other domains 
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participate in homo-and heterooligomerization must be accomplished by other techniques. 
Participation of other residues in addition to the RING domain and extreme C terminus of 
MDM2 in oligomer formation seems likely, especially concerning MDM2 homooligomers. 
In describing the purification of the MDM2 RING homo-oligomer, Linke et al.72 declared 
that the relative instability of MDM2s (residues 432–491) homooligomers could be 
improved by including additional N-terminal residues (MDM2l, residues 417–491). 
Moreover, a recent study performed by Dolezelova et al.71 suggested that MDM2 
homooligomers and MDM2–MDMX heterooligomers likely form through different 
mechanisms. Another recent study using overexpression co-immunoprecipitation 
experiments provided evidence supporting this theory, suggesting that MDM2 
homooligomers and MDM2–MDMX heterooligomers require different domains of 
MDM2.74 Thus, despite extensive similarities in the reported oligomeric RING structures of 
MDM2 RING homooligomers and MDM2–MDMX RING heterooligomers, MDM2 appears 
to bind to MDMX and other MDM2 molecules through different mechanisms, which could 
imply differences in MDM2 oligomer function or efficiency. Whether these differences in 
binding have implications on the cellular level and whether these differences have 
implications for the development of effective MDM2 inhibitors remains to be determined.
Further complicating the issue of MDM2 oligomerization, MDM2 and MDMX can form 
intramolecular interactions (Figure 3). The MDM2 RING domain can fold back and bind the 
AD, thereby generating additional tertiary structure that could play a role in oligomerization 
and MDM2 activity.75 Similarly, in MDMX, the p53-binding domain and the RING domain 
can each fold back and interact intramolecularly with the AD, although whether the AD can 
interact simultaneously with both the p53-binding domain and the RING finger remains 
unknown.49,76 Although these interdomain interactions may have direct implications for 
previously described intermolecular oligomerization (for example, RING domain of one 
MDM2 molecule interacts with the AD of another MDM2 molecule77), intramolecular 
domain interactions likely have a more significant role based on their kinetic favorability due 
to covalent attachment. Interestingly, these intramolecular interactions have been implicated 
in MDM2 E3 ligase activity75 as well as in MDMX nuclear localization.76 Disruption of the 
MDMX RING–AD interaction increases nuclear localization, suggesting that its ability to 
bind MDM2 for nuclear import is impeded when present in the RING-AD intramolecular 
configuration. These types of studies offer hints to the supramolecular assembly of the 
MDM2 oligomers for which we do not have direct structural data. Collectively, these studies 
suggest that MDM2 ternary complexes involving p53 require more than simple RING–
RING and p53–p53-binding domain interactions.
REGULATION OF MDM2 OLIGOMERS
Based on the importance of MDM2 oligomerization for regulating p53, understanding how 
oligomer formation is regulated is of crucial importance. MDM2 and MDMX levels and 
activities are regulated in many different ways, including at the transcriptional level (p53–
MDM2/MDMX autoregulatory loops), direct binding by other proteins (ARF,78 RPL5,79,80 
RPL11,81-83 CK1α84 CK1δ32,85), subcellular localization86 and post-translational 
modifications (phosphorylation, ubiquitination and neddylation, reviewed by Wade et al.21). 
The respective ADs of MDM2 and MDMX appear to feature prominently in the regulation 
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of intermolecular interactions, including oligomerization. In addition to the newly 
discovered intramolecular interactions involving the MDM2 and MDMX ADs, binding of 
the AD by small proteins and phosphorylation of the AD likely also contribute to MDM2 
oligomer regulation. The AD–RING intervening sequence also appears to be a key 
regulatory point for MDM2 oligomerization. A study by Cheng et al.23 showed that 
phosphorylation of sequence upstream of the RING domain of MDM2 results in the 
inhibition of MDM2 RING domain oligomerization, which correlates with reduced E3 
ligase activity toward p53. Moreover, ATM-mediated phosphorylation of these residues in 
MDM2 inhibits the ability of MDM2 to oligomerize.87 Interestingly, enforced 
oligomerization using a cross-linkable FKBP domain fused to the N terminus of the MDM2 
RING domain significantly enhances MDM2 E3 activity, which provides direct evidence 
that MDM2 oligomerization is a critical point of regulation for MDM2 activity. As one 
might expect based on homology, MDMX phosphorylation at a similar region could result in 
decreased MDM2–MDMX heterooligomer formation and stabilized p53 levels as well; 
however, this remains to be tested.
MDM2 E3 ligase activity may also be regulated indirectly by manipulating MDMX. 
Because MDM2–MDMX heterooligomers are more efficient E3 ligases, it is thought that 
directing MDM2 E3 ligase activity toward MDMX could effectively reduce MDM2 E3 
activity and thus stabilize p53. In a recent study, overexpression of the small protein ARF 
could decrease MDMX levels and stabilize p53 by directing MDM2 E3 ligase activity 
toward MDMX instead of p53.58 Consistently, in the absence of ARF (as in many tumors 
that express WT p53), MDM2 E3 ligase activity appears to be less readily diverted towards 
MDMX degradation, which could explain why tumors that retain WT p53 are pressured for 
the mutation of the ARF locus. Because ARF binds to the MDM2 AD and possibly not the 
MDMX AD,88 it is tempting to speculate that the positively charged ARF is required to 
stabilize the quaternary structure between the two MDM ADs. Similar observations were 
reported for RPL11.89 In another study analyzing RPS27l knockout mouse cells, the 
induction of ribosomal stress by the absence of RPS27l resulted in MDM2-mediated 
MDMX degradation, which reduced MDM2–MDMX heterooligomer formation and 
stabilized p53.90 The effect of RP binding on MDM2 oligomer formation has not been tested 
directly; however, based on the reported effects of ARF–MDM2 binding,58 we suspect that 
RP–MDM2 binding may behave in a similar manner in terms of reducing MDM2–MDMX 
heterooligomer formation. On the basis of these studies, it would be interesting to determine 
whether ARF- or RP-mediated stabilization of MDM2 AD–MDMX AD binding could offer 
a viable method through which to generate x-ray crystallographs using the full-length 
proteins. Notably, Linke et al.72 reported that the presence of L-arginine, a positively charged 
amino acid, was necessary to obtain crystals of MDM2–MDMX RING domains. If the 
conditions for full-length crystal structures of MDM2 can be resolved, then it would be 
interesting to determine how the binding of small proteins, such as ARF or RPL11, affects 
the overall structure and substrate selection of MDM2.
MDM2–MDMX HETEROOLIGOMERS ARE REQUIRED IN VIVO
In addition to the abundance of in vitro evidence dissecting MDM2 oligomerization 
mechanics, several mouse models have been developed that offer complementary in vivo 
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platforms to investigate MDM2 oligomerization. When the results of these studies are 
analyzed in aggregate, they offer mechanistic insight as well as a clearer picture of the 
importance of MDM2 oligomerization in p53 regulation. The earliest mouse models based 
on the knockout of Mdm2 or MdmX have revealed p53-dependent embryonic lethal 
phenotypes for either gene.64,91,92 These studies were critical to show the importance of 
each of these two genes in p53 regulation. Moreover, these models show that neither MDM2 
nor MDMX can completely compensate for the deficiency of the other. Of note, 
overexpressing an Mdm2 transgene in mice can compensate for MDMX deficiency.93 
Nonetheless, although MDM2 and MDMX have been attributed with the ability to 
physically mask the p53 transactivation domain, it appears as though this activity is 
insufficient for the control of p53 during mouse development. This idea was supported by a 
study that showed that mice homozygous for the MDM2 RING domain structural mutation 
C462A, which abrogates MDM2 E3 activity and MDM2–MDMX heterooligomerization, 
die in utero in a p53-dependent manner.24 As mentioned in the preceding section, the 
corresponding human MDM2 RING mutant C464A retains the ability to form 
homooligomers under overexpressed conditions,74 which may contribute to residual p53 
inhibitory activity, as MDM2 likely requires some type of oligomerization to function 
(discussed further below).
Subsequent knock-in mouse studies have hinted at the importance of MDM2–MDMX 
heterooligomer formation for the control of p53 activity during embryonic development. 
Two similar studies by Pant et al.94 and Huang et al.95 showed that mice expressing mutant 
versions of MDMX lacking the RING domain or lacking proper RING domain structure 
display an embryonic lethal phenotype. In these mice, although the p53-binding domain of 
MDMX remains intact and MDM2 is WT, the mice die in utero in a p53-dependent manner 
(approximately day E9.5). These studies suggest that heterooligomerization is the key to p53 
control, at least during the embryonic stages of development. Interestingly, 
heterooligomerization is dispensable for p53 regulation during adulthood.94 Consistently, the 
death of these mice, as well as all embryonic lethal Mdm2/MdmX knock-in mice, 
approximately coincides with the stage in which p53 expression is dramatically and 
ubiquitously upregulated, suggesting the crucial need for effective p53 regulation during this 
stage of embryonic development (~ E8.5, Schmid et al.96). Expounding on the C462A and 
RING MDMX knock-in mouse studies, Tollini et al. showed that mice expressing an MDM2 
knock-in mutant (Y487A) that is E3-dead but retains the ability to heterooligomerize with 
MDMX are viable with no phenotypic differences under unstressed conditions.97 Because 
the Mdm2Y487A/Y487A mouse lacks the ability to ubiquitinate p53, in the context of the 
MdmX knock-in models, it appears as though MDM2–MDMX heteroligomerization is 
sufficient to control p53 during embryonic development and is dispensable during 
adulthood, whereas MDM2 E3 ligase activity is sufficient (and necessary) to control p53 in 
adult tissue, especially in the presence of stress, and is dispensable during embryonic 
development.
Another thing that is apparent from analyzing the various MDM2/MDMX mouse models is 
that MDM2 is a more effective regulator of p53 in vivo than MDMX.98 Indeed, the loss of 
MDM2 is consistently more detrimental to mice than the equivalent loss of MDMX 
(reviewed in Wade et al.98). For example, in a study of mice expressing a brain-specific Cre-
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inducible p53 allele, Francoz et al.65 showed that p53LSL/−;MdmX−/−;Nes-Cre mice 
survived birth, whereas p53LSL/−;Mdm2−/−;Nes-Cre mice died during development. In this 
study, assuming Cre-mediated gene excision occurred at similar efficiencies in the two mice, 
the presence of MDM2 alone resulted in a better outcome than the presence of MDMX 
alone. This trend is noticeable in other mouse models as well. Knockout mice homozygous 
for Mdm2 deletion die at a slightly yet consistently earlier embryonic stage when compared 
with homozygous MdmX knockout mice (E5.5 for MDM2-null vs E7.5 for MDMX-null 
mice).64,91,92 Consistent with a more severe phenotype, Mdm2 knockout mice display 
extensive apoptosis, whereas MdmX knockout mice display extensive cell cycle arrest.99 In 
another study, brain-specific loss of Mdm2 in mice resulted in death at E12.5 compared with 
brain-specific loss of MdmX, which resulted in death at E17.5.100 Moreover, using a 
tamoxifen-inducible p53 fusion protein (p53ER) expressed in mice, the Evan lab showed in 
separate studies that the activation of p53ER in adult Mdm2−/− mice results in lethality 
around 5 days, whereas p53ER activation in adult MdmX−/− mice results in lethality in ~29 
days.101,102 Interestingly, mice harboring an E3-dead, heterooligomerization-deficient 
MDM2C462A/C462A mutant die around E7.5, which is closer to the MDMX-null mutant 
mouse, suggesting that MDM2C462A might possess residual ability to inhibit p53 that is not 
present in the MDM2-null mice.24 What could explain the ability of the MDM2-C462A 
mutant to inhibit p53 in vivo? One possibility is the p53-binding domain, which can still 
bind to p53 in vivo.24 The MDM2 p53-binding domain actually displays a three- to four-fold 
greater affinity for p53 than that of MDMX, which suggests that the presence of the MDM2 
p53-binding domain in the Mdm2C462A/C462A mice offers an advantage in transcriptional 
suppression over that of the MDMX p53-binding domain, which is also present in these 
mice. Physical MDM2C462A–p53 interaction could contribute to the delay in death of mice 
that express the MDM2 p53-binding domain compared with mice that do not (for example, 
Mdm2C462A/C462A mice vs MdmX knockout mice103,104), although further experiments will 
be required for confirmation. Moreover, although it is possible that MDM2C462A protein 
retains the ability to suppress p53 through direct binding of the p53 transactivation domain, 
whether the homooligomerization capacity of MDM2 is required remains to be determined 
in vivo.
The MDM2–MDMX heterooligomer is a clearly more efficient E3 ligase platform than the 
MDM2 homooligomer.39,62 However, the secret behind the increased ligase efficiency of the 
heterooligomer (as well as the basic requirement for MDMX, which lacks E3 activity) 
remains a mystery. Structural data imply that MDMX binding to MDM2 creates a unique 
platform capable of more efficiently transferring the ubiquitin molecule from the E2 to 
p53.72,73 However, other models cannot be excluded based on the current data. For example, 
MDM2 is commonly thought to bind directly to the E2. However, because direct evidence 
for E2 binding to MDM2 remains elusive, it is conceivable that MDMX could bind to and 
transport the cognate E2 to MDM2, which in turn catalyzes the transfer of ubiquitin to p53. 
Circumstantial evidence in support of this possibility includes the currently inexplicable 
observation that overexpression of MDMX in the presence of many different types of E3-
dead MDM2 constructs can rescue MDM2 E3 ligase activity.70,97,105 If MDMX is able or 
necessary to transport the E2-Ub to MDM2, then overexpression of MDMX could increase 
the intracellular concentration of MDM2–MDMX–Ub complexes in the cell, forcing the 
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transfer of Ub to p53 and resulting in E3 ligase rescue. Observations in our lab suggest that 
MDMX shows specific binding to the E2 UbcH5 when compared with MDM2 (unpublished 
observations). Another consideration is that MDMX could bind to a different E2 than 
MDM2 does resulting in the targeting of different lysine residues or in the conjugation of 
differently linked Ub chains. The endogenous E2 associated with MDM2-dependent 
ubiquitination of p53 has not yet been confirmed, thus speculation persists regarding 
MDM2–MDMX-mediated ubiquitin transfer to p53. Perhaps the greatest advances in 
predicting and understanding MDMX enhancement of MDM2 E3 ligase activity could be 
achieved through the analysis of complete full-length crystal structures of the 
heterooligomer compared with the homooligomer.
MDM2–MDMX HETEROOLIGOMERIZATION IS IMPORTANT, WHAT ABOUT 
MDM2 HOMOOLIGOMERIZATION?
A uniting factor in all of the MDM2/MDMX mutant mouse models is that the presence of 
MDM2 (even structural mutant MDM2C462A) is sufficient to delay lethality. Notably, prior 
to the evolution of MDMX, MDM2 was tasked with the regulation of p53 for organismal 
survival. Thus, although MDM2 likely retains the ability to inhibit p53 by itself, the 
predominant mechanism of MDM2-mediated p53 inhibition in vivo remains to be 
determined. Early evidence has suggested that the direct binding of MDM2 to p53 is 
sufficient to suppress p53 activity.15,16 Although direct binding and inhibition of p53 could 
account for this delay in lethality, whether MDM2 homooligomerization also contributes to 
p53 degradation/inhibition in vivo is unknown. Studies confirming the in vivo existence and 
the role of MDM2 homooligomers need to be conducted; however, inherent difficulties are 
associated with analyzing MDM2 homooligomers in vivo because of the identical nature of 
the alleles of MDM2. With the increasing popularity and standardization of modern-era 
genome editing tools, a useful mouse or genome-edited cell model that could address these 
questions is one that expresses different epitope tags on each of the two MDM2 alleles. Cells 
expressing endogenous levels of multiple epitope-tagged MDM2 alleles could be used to 
confirm the existence of MDM2 homooligomers under physiological conditions. Another 
MDM2 knock-in model of interest is an MDM2 mutant that selectively prevents 
homooligomer formation while leaving heterooligomer formation intact. This model could 
be used to determine how the abrogation of MDM2 homo-oligomers under physiological 
conditions affects MDM2 function and organismal fitness. Although point mutations may 
not be sufficient to achieve the selective inhibition of MDM2 homo-oligomers, the deletion 
of AD residues appears to confer a selective defect in MDM2 homooligomer formation 
while leaving MDM2–MDMX heterooligomerization and E3 ligase activity largely intact, at 
least under overexpressed conditions.74 Because E3 ligase activity appears to remain intact 
in the presence of MDM2 AD deletion constructs,106,107 one would expect viable offspring. 
However, the construction of a conditional knock-in mutant mouse harboring an inducible 
deletion of the Mdm2 AD could be a worthwhile endeavor to determine the effect of Mdm2 
AD deletion on survival and p53 stability during the adult stages. A better understanding of 
how MDM2 oligomers form and function in vivo could provide valuable insight into the 
design of MDM2-targeting drugs.
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TARGETING THE MDM2 OLIGOMER
Considering their crucial role in p53 regulation, particularly in the context of DNA damage, 
targeting MDM2/MDMX is a promising avenue of pharmacological research. MDM2/
MDMX dual inhibitors could be particularly effective in tumors that overexpress these 
targets and harbor WT p53 (Figure 4). Nonetheless, most compounds developed to date offer 
relatively specific MDM2 inhibition by targeting the p53-binding domain on MDM2.108,109 
These inhibitors have been carefully optimized, and some have shown strong efficacy in 
preclinical studies; however, their efficacy in patients has been underwhelming. The lack of 
clinical success with MDM2 inhibitors can be attributed to multiple factors, the most 
prominent of which is on-target toxicity.110 Thus, although highly potent MDM2 inhibitors 
are currently available (RG7112, Kd = 11 nM; MI-888, Kd = 0.44 nM; RO-5963, IC50 = 33 
nM), better targeting mechanisms or dosing optimization, perhaps by combining MDM2 
inhibitors with other therapies, may be necessary to achieve the best patient outcomes. 
However, even if side effects could be minimized, it is possible that MDM2 inhibition alone 
could be ineffective for several types of cancers.111 For example, inhibitors that target only 
MDM2 and not MDMX, such as nutlin-3a (400-fold less effective against MDMX than 
against MDM2), are ineffective against cancer cells that over-express MDMX presumably 
due to MDMX-mediated inhibition of p53.112-114 Moreover, long-term treatment with 
MDM2 inhibitors introduces a selective pressure that could promote the development of p53 
mutations and multi-drug resistance.115,116 Another issue unique to MDM2-specific 
inhibitors is the requirement for high doses of the drug to counter the p53-regulated increase 
in MDM2 expression as a result of inhibiting MDM2 in the first place. Although some of 
these issues also apply to MDM2/MDMX dual inhibitors, current efforts in MDM2 
inhibition have paid more attention to the effects of MDMX as well.
Differences in the structures of the p53 binding pockets of MDM2 and MDMX present a 
challenge to the development of drugs that effectively target both molecules.117 Nonetheless, 
recent drug candidates have emerged that simultaneously target MDM2 and MDMX118-120 
(see Khoo et al.121 and Burgess et al.122 for detailed reviews of MDM2 drugs). In a study by 
Graves et al.,120 the authors show that RO-5963, an indolyl hydantoin derivative, binds the 
p53 binding pocket of MDM2 and MDMX with similar affinities in vitro. Moreover, 
RO-5963 binding simultaneously engages MDM2 and MDMX, resulting in the enforced 
oligomerization of the two molecules. This results in p53 stabilization and cell death in 
several cancer cell lines, especially in cancer cells expressing high levels of MDMX, which 
is a promising proof-of-principle example of dual MDM2–MDMX inhibition. Although the 
clinical utility of this compound as a single agent may not be likely possibly due to the 
compensatory induction of MDM2, the use of compounds such as RO-5963 in conjunction 
with other p53-activating compounds may prove effective for certain types of tumors.
In addition to preventing interaction with p53, other methods of inhibiting MDM2 and 
MDMX have involved the inhibition of E3 ligase activity and MDM2/MDMX 
heterooligomerization. Early studies suggested that the MDM2–MDMX RING–RING 
oligomer was not an attractive drug target due to the lack of a defined catalytic site and a 
predominantly hydrophobic interaction-based binding mechanism.72,73 Nonetheless, 
experimental evidence has suggested that the inhibition of MDM2–MDMX 
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heterooligomerization could be effective, as MDMX RING domain overexpression 
competes for MDM2 binding, inhibits endogenous MDM2–MDMX oligomer formation, 
and results in the stabilization and activation of p53.62,123 Small molecules that inhibit 
MDM2 enzymatic activity have been reported, including HLI98 and MDM2 E3 Ligase 
(MEL) inhibitors. Although HLI98 showed specificity for MDM2 inhibition in vitro, it also 
displayed non-specific effects and p53-independent effects at higher concentrations in cells 
as well as poor pharmacological characteristics overall.124 A more promising candidate of 
the MDM2 ligase inhibitor class, the MEL series of inhibitors (MEL23 and MEL-24) 
showed specific inhibition of MDM2–MDMX E3 ligase activity, stabilization of p53 and the 
induction of apoptosis in a p53-dependent manner.125 Although more work using in vivo 
models is required to validate the MEL inhibitors, targeting MDM2–MDMX enzymatic 
activity may not be as difficult as once thought. In an even more recent study using 
computational and rational methods, a peptide-based inhibitor of MDM2–MDMX 
oligomerization was reported.126 This inhibitor, named Peptide3, showed a p53-dependent 
apoptotic response; however, its reported mechanism of action is peculiar in that only 
nuclear MDM2–MDMX heterooligomerization is affected. Perhaps using a more thorough 
and unbiased screening method, such as phage display, coupled with emerging peptide 
technologies, such as peptide stapling, could yield even more effective peptide-based 
MDM2–MDMX oligomerization inhibitors.
Another area of intense research includes the development of p53 mimetic stapled peptides. 
In a study by Chang et al., the authors describe a stapled α-helical peptide that binds to the 
p53-binding domains of MDM2 and MDMX with low-nanomolar affinities.118 Although 
controversial, stapled peptide technology offers the unique opportunity to specifically mimic 
the p53-binding site in MDM2 and/or MDMX with strong affinity. It will be interesting to 
see how far stapled peptide drug candidates, such as ATSP-7041, can progress through 
clinical trials.
EXPANDING THE TUMOR SPECTRUM OF MDM2 INHIBITORS
What is even more exciting is how the spectrum of tumors that respond to drugs that inhibit 
MDM2 oligomerization and function (WT p53 and/or overexpressing MDM2/MDMX) 
could be increased by combining them with complementary drugs that also target the 
MDM2/MDMX–p53 pathway. For example, the compound APR-246 (also known as 
PRIMA-1MET), a mutant p53 reactivator, has shown some promise in patients harboring 
mutant p53 tumors in an early-stage clinical trial.127 The combination of APR-246 with 
various standard chemotherapeutics has also shown synergistic effects in the treatment of 
cancer cells and warrants further investigation.128-130 Moreover, considering the reduced 
efficacy of MDM2 inhibitors in many p53 mutant tumors as well as the selective pressure 
that MDM2 inhibitors, such as nutlin-3a, exert on tumors to develop p53 mutations,115,116 
p53 mutant reactivators could be effective adjuvants to increase the scope of MDM2/MDMX 
inhibitors. In fact, because many p53 mutations result in gain-of-function phenotypes,8 the 
treatment of p53 mutant tumors with MDM2 inhibitors may actually require p53 
reactivation.
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Another therapeutic modality being investigated is the use of aptamers, short single-stranded 
DNA or RNA constructs that can be engineered to bind specific proteins. Although delivery 
of nucleic acids remains an obstacle, aptamers offer the ability to specifically target 
deleterious point mutations characteristic of tumors, such as the p53 mutation R175H.131 
Moreover, delivery of p53R175H aptamers via nanoparticles showed impressive efficacy in 
a mouse xenograft tumor model. Similarly to the potential for PRIMA-1MET synergism with 
MDM2 inhibitors, aptamers could also be useful adjuvants to expand the effective tumor 
profile of MDM2 inhibitors.
Because cancer is a heterogenous disease with multiple subclonal populations, future 
curative cancer treatment attempts may focus on targeting all of the tumor clone subsets. 
Because aberrant p53 signaling is an early event in many types of tumors, combining direct 
p53-targeting treatments with drugs that target upstream factors like MDM2 inhibitors could 
result in synergistic effects that could be effective in many types of tumors. Although no 
p53-activating drugs have been approved for clinical use, the future of p53-targeting drugs 
offers a promising, relatively unexplored avenue through which a broad array of tumors may 
be treated.
CONCLUDING REMARKS
Although we have made great progress in understanding MDM2 oligomerization and how 
MDM2 can affect tumor development, basic concepts remain to be determined. Some 
crucial aspects about MDM2 oligomerization that remain to be discovered include the 
following: How does MDMX enhance MDM2 E3 ligase activity toward p53? What role do 
MDM2 homooligomers play in vivo? What mechanisms control the direction of MDM2 E3 
activity toward p53 vs other substrates (for example, MDMX)? What residues of MDM2 are 
necessary for homo- vs heterooligomerization? Are other domains of MDM2 worthy targets 
for the development of small molecules that can activate p53? As we ponder new methods to 
address these questions, we eagerly anticipate new insights from the brilliant minds of the 
MDM2/p53 field.
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Figure 1. 
MDM2 and MDMX share significant homology. MDM2 and MDMX harbor similar 
structural domains, including an N-terminal p53-binding domain, a central acidic domain 
and C4 zinc finger domain, and a C-terminal RING domain. The central AD and Zn regions 
serve as binding sites for several small proteins, including ribosomal proteins and ARF, any 
of which results in the inhibition of MDM2 E3 ligase function. MDM2 can bind to other 
MDM2 molecules of to MDMX through their respective C-terminal RING domains. In 
contrast to MDMX, MDM2 possesses a nuclear localization sequence (NLS), a nuclear 
export sequence (NES) and a cryptic nucleolar localization sequence (NoLS). Moreover, 
whereas MDM2 exerts E3 ligase activity toward p53, MDMX does not possess appreciable 
E3 ligase activity. Red circles indicate phosphorylation sites. AD, acidic domain; CK, casein 
kinase; p53 BD, p53 binding domain; RING, really interesting new gene domain; Zn, C4 
zinc finger domain.
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Figure 2. 
Many different p53 regulatory mechanisms are channeled through MDM2. MDM2 is 
modified post-translationally (phosphorylation by DNA damage kinases) or by direct protein 
binding (RPs and ARF) in response to various stresses (cues). When affected by any of the 
MDM2 inhibitors, MDM2 loses its ability to bind to and regulate p53, resulting in stabilized 
p53 levels and increased p53 transcriptional activity. Ablation of any of the three arms of 
MDM2 regulation severely impairs the activation of p53 in response to the corresponding 
stress cue. Red circles denote phosphorylation sites, the blue lines denote the binding sites of 
the indicated RP, and the black line represents the binding site of ARF. The inhibitors boxed 
in red have been shown to affect MDM2 homo- or heterooligomer formation. ARF, 
alternative reading frame.
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Figure 3. 
MDM2 and MDMX form intramolecular interactions. Recent studies have shown that 
MDM2 forms intramolecular interactions that involve RING–AD interactions. MDMX is 
also capable of RING–AD and p53 BD–AD intramolecular interactions. The implications of 
these intramolecular interactions remain unclear particularly in terms of function and 
oligomerization. However, these intramolecular interactions have clear effects on p53 
regulation and likely effects on MDM2–MDMX oligomerization. AD, acidic domain; p53, 
p53 binding domain; RING, really interesting new gene domain.
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Figure 4. 
Reactivation, inactivation and stabilization of p53 through direct means or through MDM2/
MDMX inhibition has shown promise. The MDM2/MDMX-p53 pathway is currently being 
targeted through two broad mechanisms: MDM2/MDMX inhibition through small 
molecules (RO-5963, MEL23/24, HLI98) and stapled peptides (ATSP-7041) and mutant p53 
reactivation through compounds such as APR-246 and inactivation through compounds such 
as aptamers. MDM2/MDMX inhibition could be particularly useful for p53 WT tumors, 
whereas mutant p53 reactivation/inactivation could be useful for mutant p53 tumors and for 
the expansion of the tumor spectrum for which MDM2 inhibitors may be used. Mutp53: 
mutant p53, WTp53: wild-type p53.
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